425 related articles for article (PubMed ID: 29846825)
1. Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline?
Elalouf O; Chandran V
Curr Rheumatol Rep; 2018 May; 20(7):36. PubMed ID: 29846825
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
[TBL] [Abstract][Full Text] [Related]
3. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
4. Novel Therapeutic Approaches and Treatment Targets for Psoriatic Arthritis.
Benfaremo D; Paci V; Luchetti MM; Gabrielli A
Curr Pharm Biotechnol; 2021; 22(1):85-98. PubMed ID: 32988348
[TBL] [Abstract][Full Text] [Related]
5. Switching biologics in the treatment of psoriatic arthritis.
Merola JF; Lockshin B; Mody EA
Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
[TBL] [Abstract][Full Text] [Related]
6. Psoriatic Arthritis: Newer and Older Therapies.
Chao R; Kavanaugh A
Curr Rheumatol Rep; 2019 Dec; 21(12):75. PubMed ID: 31865449
[TBL] [Abstract][Full Text] [Related]
7. Biological and synthetic target DMARDs in psoriatic arthritis.
Silvagni E; Bortoluzzi A; Ciancio G; Govoni M
Pharmacol Res; 2019 Nov; 149():104473. PubMed ID: 31585178
[TBL] [Abstract][Full Text] [Related]
8. Management of Psoriatic Arthritis: Traditional Disease-Modifying Rheumatic Agents and Targeted Small Molecules.
Soriano ER
Rheum Dis Clin North Am; 2015 Nov; 41(4):711-22. PubMed ID: 26476228
[TBL] [Abstract][Full Text] [Related]
9. Biological agents in psoriatic arthritis.
Kocijan R; Muschitz C; Rech J
Wien Med Wochenschr; 2015 Jan; 165(1-2):36-9. PubMed ID: 25205184
[TBL] [Abstract][Full Text] [Related]
10. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
[TBL] [Abstract][Full Text] [Related]
11. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
Front Immunol; 2024; 15():1395968. PubMed ID: 38846940
[TBL] [Abstract][Full Text] [Related]
12. Updated therapies for the management of Psoriatic Arthritis.
Toussi A; Maverakis N; Le ST; Sarkar S; Raychaudhuri SK; Raychaudhuri SP
Clin Immunol; 2020 Nov; 220():108536. PubMed ID: 32681979
[TBL] [Abstract][Full Text] [Related]
13. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
14. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
15. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
16. Treatment of spondyloarthropathy: the potential for agents other than TNF inhibitors.
Her M; Kavanaugh A
Curr Opin Rheumatol; 2013 Jul; 25(4):455-9. PubMed ID: 23680779
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying antirheumatic drug therapy for psoriatic arthritis.
Salvarani C; Cantini F; Olivieri I
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S71-5. PubMed ID: 12463452
[TBL] [Abstract][Full Text] [Related]
18. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the management of psoriatic arthritis.
Mease PJ
Curr Opin Rheumatol; 2004 Jul; 16(4):366-70. PubMed ID: 15201598
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Gan EY; Chong WS; Tey HL
BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
